



# Discovery Fast Track Challenge



## Helpful Tips for Technology Transfer Offices

### About the submission process.


- Useful and specific information for TTOs about the Discovery Fast Track Challenge is available at [www.gsk.com/discoveryfasttrack](http://www.gsk.com/discoveryfasttrack). Sign up under Challenge News to receive regular updates from the GSK team.
- One-page non-confidential proposals may be submitted directly via the website. As part of this process, investigators are required to supply contact details for the relevant TTO. GSK requires acknowledgement and approval from the TTO prior to initiating the review of Discovery Fast Track proposals. If TTO approval is not subsequently given, proposals will be withdrawn and the information destroyed.
- TTO offices should ideally provide a single contact name for their institution to the GSK administrator at [DiscoveryFastTrack@gsk.com](mailto:DiscoveryFastTrack@gsk.com) so that the TTO can be notified of any submissions from that campus. GSK can provide assistance on how to create a special account for the institutional TTO representative that allows them to see all submissions from their institution.
- Submissions are open from February 24 to April 23 in Europe and from February 24 to May 16 in North America. Please encourage investigators in your institution to submit their proposals as early as possible. In addition, it would be helpful if TTOs review and approve submissions *as soon as possible* after the above notification from GSK, so that proposals can be moved into the review process in a timely way.
- In case of submissions close to the deadline date, or if the TTO needs more time due to the complexities of a particular submission, GSK has provided a short window after the submission deadline for TTOs to finish their review and provide approval of the submission. **If a submission is NOT approved by the TTO within one week of the relevant submission deadline, the submission will be automatically disqualified from the Discovery Fast Track Challenge.**
- If a TTO determines that a submission contains confidential information that must be extracted from the proposal in accordance with the challenge rules, a revised proposal should be **sent to the GSK administrator at [DiscoveryFastTrack@gsk.com](mailto:DiscoveryFastTrack@gsk.com) by the deadline listed above.**

Continued...

## Points to bear in mind when reviewing a submission.

- **Concept and associated material:** Are there any existing MTAs with obligations? Are there any associated license or bailment agreements? Are there any other obligations or restrictions associated with the concept or material (or reagents required to create the materials—such as plasmids, vectors, dyes, etc.)? Can all materials be used by a commercial entity, or are additional licenses required? Is there an existing and related invention case or portfolio that is not conducive to the rules of the challenge? Does the submission contain confidential information that should be removed, e.g. might preclude the university from obtaining patent protection later? Are there any limitations to GSK's ability to use the materials/target for commercial purposes?
- **Submission applicant (and other persons involved in developing the submitted concept):** Does their research program funding sources and collaborations (including research awards, MTAs, non-profit awards, collaboration or licensing agreements, visitor agreements for the laboratory, and projects) have overlapping scopes of work and funding with obligations and/or restrictions that would prevent GSK and the investigator from proceeding with the research outlined in the proposal? Are there any third-party obligations (e.g., licensing agreements) that might conflict with the challenge rules and agreements?

## Workflow for Discovery Fast Track Challenge



### Four possible research outcomes:

**Outcome One:** GSK and institution agree to continue research under a DPAC agreement to be negotiated; likely research funding available. If no agreement, GSK can elect outcome #3.

**Outcome Two:** Institution wants to continue research; GSK does not. GSK will provide chemical probes to institution under an agreement or for a (likely) joint publication.

**Outcome Three:** GSK wants to continue Research; Institution does not. GSK gets a license to patents claiming material in exchange for milestone payments.

**Outcome Four:** Neither party wants to continue research or no useful chemical probes are identified from the screen. GSK may opt to proceed at a later date after reconsideration and discussion with institution (per MTA).

